biohaven: "rimegepant pivotal phase 3 trial results -- conference call." .
subscribe to breaking news emails
stephen silberstein, md, director, jefferson university headache center. .
but what if it had happened in one of the maine schools where the rate is 10 percent or more?
.favorites
.